In September the Clinical Center was named the 2011 recipient of the Lasker–Bloomberg Public Service Award from the Albert and Mary Lasker Foundation, an organization that has recognized outstanding advances in medical research each year since 1945. The award description recognizes the CC for spearheading major advances in a wide array of medical arenas, establishing an example for academic institutions across the country, and training thousands of investigators, many of whom now lead academic and research institutions across the world.
Ask five different astrophysicists to define a black hole, the saying goes, and you’ll get five different answers. But ask five biomedical researchers to define systems biology, and you’ll get 10 different answers . . . or maybe more.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) marked its 25th anniversary with a scientific symposium to commemorate a quarter-century of research, training, and information dissemination in disease areas that affect nearly every home in America. NIH Director Francis Collins, NIAMS Director Stephen Katz, Research!America Chairman John Edward Porter, and panels of patients, scientists, and clinicians reminisced about NIAMS to a packed Lipsett Amphitheater in June.
“Medical discoveries of tomorrow depend on the students we train today,” said NIH Director Francis Collins. In September 2012, a new NIH Medical Research Scholars Program “will help ensure that there is a steady pipeline of scientists conducting the full range of biomedical research.”
A dozen second-year residents—in pediatrics, internal medicine, and neurology—from regional academic medical centers—visited the NIH Clinical Center recently at NIH’s first Resident Research Career Day, held on October 17.
New Technique Identifies First Events in Tumor Development
NIAMS AND NCI RESEARCH NEWS
A novel technique that enables scientists to measure and document tumor-inducing changes in DNA is providing new insights into the earliest events involved in the formation of leukemias, lymphomas, and sarcomas and could potentially lead to the discovery of ways to stop those events.